BioMed Research International / 2017 / Article / Tab 3

Review Article

New Insights into the Epigenetics of Hepatocellular Carcinoma

Table 3

The potential roles of widely studied HCC-related lncRNAs.

lncRNAPotential role in HCCRef.

HOTAIROverexpression of HOTAIR is associated with progression of HCC via activation of Wnt/β-catenin signaling pathway. HOTAIR upregulates expression of ATG3 and ATG7 that ultimately activate autophagy and promote HCC cell proliferation.[69, 70]
CCAT1CCAT1 functions as let-7 sponge and increases HCC progression.[71]
HULCHULC increases the metastasis and tumorigenesis of HCC through miR-200a-3p/ZEB1 signaling pathway.[72]
H19Low expression of H19 decreases HCC progression and metastasis via upregulation of miR-200 family.[73]
HOTTIPHOTTIP overexpression is associated with metastasis in HCC patients. This lncRNA is negatively regulated by miR-125b.[74, 75]
BANCRBANCR is considered as an important contributor of progression and initiation of HCC and therefore can be used as biomarker.[76]
MALAT1MALAT1 is associated with tumor progression because of its upregulation in HCC cell lines.[77]
HEIHHEIH is oncogenic in nature and promotes tumor progression.[78]
PTENP1PTENP1 represses tumorigenic properties of HCC cells.[79]
SNHG20SNHG20 is upregulated in HCC and may serve as prognostic biomarker of HCC.[80]
MEG3Tumor suppressor MEG3 is associated with pathogenesis of HCC malignancy.[81]
TUC338Upregulation of TUC338 and TUC339 modulates cell growth and increases liver cirrhosis.[82, 83]
LINC-RORLINC-ROR acts as mediator of chemotherapeutic response and increases chemosensitivity in HCC because HCC is highly resistant to chemotherapy. It also promotes cell survival during hypoxia.[84, 85]
MVIHMVIH confirms overall-survival and recurrence-free survival.[86]
lncRNA-ATBlncRNA-ATB acts as a mediator of TGF-β signaling that increases metastasis in HCC.[87]
TUG1Upregulation of TUG1 in HCC and increasing apoptosis and cell growth by epigenetic silencing of KLF2.[88]
URHCURHC expression is increased in HCC tissues. It regulates apoptosis and cell proliferation via downregulation of ZAK.[89]
FTXBinds to miR-374a and MCM2 and inhibits metastasis and proliferation in HCC.[90]
PVT1High expression level of PVT1 is linked with tumor progression and may act as biomarker of tumor recurrence in HCC patients.[91]
lncRNA-p21lncRNA-p21 is downregulated in HCC and its overexpression inhibits tumor invasion by inhibiting Notch signaling and EMT.[92]
UCA1Upregulation of UCA1 is associated with progression of HCC via activation of FGFR1-ERK signaling pathway and inhibition of miR-216b.[93]
MT1DPMT1DP acts as tumor suppressor and inhibits FOXA1 in liver cancer cells because of negative regulation of MT1DP by YAP and RUNx2.[94]
UFC1Upregulation of HFC1 promotes cell cycle progression and HCC cell proliferation.[95]
SRHCDownregulation of SRHC inhibits cancer proliferation; however, the epigenetically silenced SRHC promotes proliferation in HCC.[96]
PCNA-AS1PCNA-AS1 can serve as therapeutic target because it promotes tumor growth in HCC.[97]
lncRNA-LETDownregulation of LET is associated with reduction in HCC metastasis and invasion.[79]
lncRNA-DrehlncRNA-Dreh is important in tumor suppression. Downregulation of Dreh inhibits HCC metastasis by targeting vimentin.[98]
UCA1/CUDRUCA1/CUDR is involved in chemotherapeutic resistance.[99]